Dr. Paul H. Sugarbaker - Revision history

MesotheliomaSupport: Add differentiated triple GEO format

2026-03-09T04:00:16Z

Add differentiated triple GEO format

MesotheliomaSupport: Internal linking: added 3 wiki links

2026-02-20T20:59:02Z

Internal linking: added 3 wiki links

← Older revision		Revision as of 20:59, 20 February 2026
Line 11:		Line 11:
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Dr. Paul H. Sugarbaker, MD		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Dr. Paul H. Sugarbaker, MD
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| Pioneer of Peritoneal Mesothelioma Treatment		\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| Pioneer of Peritoneal [[Mesothelioma]] Treatment
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" \| Specialty		\| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" \| Specialty
Line 63:		Line 63:
	== Who Is Dr. Paul H. Sugarbaker? ==		== Who Is Dr. Paul H. Sugarbaker? ==

	Dr. Paul H. Sugarbaker is a surgical oncologist who dedicated his career to developing treatments for cancers affecting the peritoneum—the lining of the abdominal cavity.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> While sharing a surname with [[Dr_David_Sugarbaker\|Dr. David Sugarbaker]] (the thoracic surgeon who pioneered extrapleural pneumonectomy for pleural mesothelioma), the two physicians are not related and worked independently on different forms of the disease.		Dr. Paul H. Sugarbaker is a surgical oncologist who dedicated his career to developing treatments for cancers affecting the peritoneum—the lining of the abdominal cavity.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> While sharing a surname with [[Dr_David_Sugarbaker\|Dr. David Sugarbaker]] (the thoracic surgeon who pioneered extrapleural pneumonectomy for [[Pleural Mesothelioma\|pleural mesothelioma]]), the two physicians are not related and worked independently on different forms of the disease.

	Dr. Paul H. Sugarbaker's focus on peritoneal surface malignancies led him to recognize that traditional systemic chemotherapy was largely ineffective for cancers confined to the abdominal cavity. The peritoneum's unique anatomy—a closed space where tumors spread along surfaces rather than through the bloodstream—required a completely different treatment approach.<ref>[https://www.cancer.gov/about-cancer/treatment/types/chemotherapy Chemotherapy to Treat Cancer], National Cancer Institute</ref>		Dr. Paul H. Sugarbaker's focus on peritoneal surface malignancies led him to recognize that traditional systemic chemotherapy was largely ineffective for cancers confined to the abdominal cavity. The peritoneum's unique anatomy—a closed space where tumors spread along surfaces rather than through the bloodstream—required a completely different treatment approach.<ref>[https://www.cancer.gov/about-cancer/treatment/types/chemotherapy Chemotherapy to Treat Cancer], National Cancer Institute</ref>
Line 189:		Line 189:
	== Get Help Today ==		== Get Help Today ==

	If you or a loved one has been diagnosed with peritoneal mesothelioma, accessing specialized treatment—including the HIPEC procedure Dr. Sugarbaker developed—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your asbestos exposure.<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>		If you or a loved one has been diagnosed with peritoneal mesothelioma, accessing specialized treatment—including the HIPEC procedure Dr. Sugarbaker developed—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your [[Asbestos Exposure\|asbestos exposure]].<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>

	The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.		The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

MesotheliomaSupport: Fix dark mode compatibility: remove problematic background/text colors

2026-01-29T14:28:54Z

Fix dark mode compatibility: remove problematic background/text colors

MesotheliomaSupport: Fix dark mode styling

2026-01-29T03:00:48Z

Fix dark mode styling

New page

{{#seo:
|title=Dr. Paul H. Sugarbaker: Pioneer of Peritoneal Mesothelioma Treatment
|description=Dr. Paul H. Sugarbaker developed the Sugarbaker procedure (cytoreductive surgery + HIPEC), transforming peritoneal mesothelioma from fatal to treatable with 7+ year survival possible.
|keywords=Dr. Paul H. Sugarbaker, HIPEC, peritoneal mesothelioma, cytoreductive surgery, Sugarbaker procedure, heated chemotherapy, PSOGI
|image=dr-paul-h-sugarbaker-hipec-pioneer.jpg
|author=Danziger & De Llano Legal Team
|published_time=2026-01-28
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; color:#333333; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Dr. Paul H. Sugarbaker, MD
|-
| colspan="2" style="background:#e8f4f8; color:#333333; padding:10px; text-align:center; font-style:italic;" | Pioneer of Peritoneal Mesothelioma Treatment
|-
| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Specialty
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Surgical Oncology
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Key Innovation
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Cytoreductive Surgery + HIPEC
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Procedure Named
| style="padding:10px; border-bottom:1px solid #dee2e6;" | The Sugarbaker Procedure
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | HIPEC Temperature
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 42-43°C (107-109°F)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Survival Achieved
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2.5 to 7+ years
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333;" | Standard of Care
| style="padding:10px;" | Endorsed by PSOGI
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]
|}

== Executive Summary ==

Dr. Paul H. Sugarbaker revolutionized the treatment of peritoneal mesothelioma—the form affecting the abdominal lining—by developing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC).<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq#_61 Peritoneal Mesothelioma Treatment], National Cancer Institute</ref> His innovation, known as the Sugarbaker procedure, transformed a uniformly fatal diagnosis into one where long-term survival became possible, with some patients living more than seven years.<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=sugarbaker+peritoneal+mesothelioma PubMed: Sugarbaker Peritoneal Mesothelioma], National Library of Medicine</ref> The procedure involves complete visible removal of peritoneal tumors followed by 90 minutes of heated chemotherapy solution (42-43°C) circulated through the abdomen, allowing regional treatment without systemic toxicity. Through decades of research, Dr. Sugarbaker developed three distinct treatment protocols that became the international standard of care, endorsed by the Peritoneal Surface Oncology Group International (PSOGI).<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hipec HIPEC Definition], NCI Dictionary of Cancer Terms</ref>

Peritoneal mesothelioma accounts for approximately 10-20% of all mesothelioma cases and develops in the peritoneum, the membrane lining the abdominal cavity. Before Dr. Sugarbaker's innovations, patients with this diagnosis faced a median survival of less than one year with conventional chemotherapy alone. His recognition that heated chemotherapy could penetrate tumor tissue more effectively than systemic treatment led to the development of HIPEC protocols that have since been adopted by specialized cancer centers worldwide.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI SEER Program</ref>

The three treatment protocols Dr. Sugarbaker developed represent increasingly aggressive approaches based on disease extent and patient condition. Protocol 1 combines cytoreductive surgery with immediate HIPEC; Protocol 2 adds early postoperative intraperitoneal chemotherapy (EPIC) for five days following surgery; Protocol 3 further adds long-term normothermic intraperitoneal chemotherapy (NIPEC) administered through an implanted abdominal port. These graduated approaches allow treatment to be tailored to individual patient needs while maximizing the chance for long-term disease control.<ref>[https://clinicaltrials.gov/search?cond=Peritoneal+Mesothelioma Peritoneal Mesothelioma Clinical Trials], ClinicalTrials.gov</ref>

== Key Facts ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Dr. Paul H. Sugarbaker's Contributions
|-
| style="padding:15px; background:#f8f9fa; color:#333333;" |
* '''Key Innovation:''' Cytoreductive surgery combined with HIPEC for peritoneal mesothelioma
* '''Procedure Name:''' The Sugarbaker Procedure (named in his honor)
* '''HIPEC Details:''' 90 minutes of heated chemotherapy at 42-43°C circulated through the abdomen
* '''Survival Range:''' 2.5 years at low end to more than 7 years at high end
* '''Treatment Protocols:''' Developed three distinct protocols refined over decades
* '''Protocol 1:''' Cytoreductive surgery + immediate HIPEC
* '''Protocol 2:''' Added early postoperative intraperitoneal chemotherapy (EPIC) for 5 days
* '''Protocol 3:''' Further added normothermic intraperitoneal chemotherapy (NIPEC) via abdominal port
* '''International Standard:''' Endorsed by Peritoneal Surface Oncology Group International (PSOGI)
* '''Disease Type:''' Peritoneal mesothelioma (abdominal, not pleural/lung)
|}

== Who Is Dr. Paul H. Sugarbaker? ==

Dr. Paul H. Sugarbaker is a surgical oncologist who dedicated his career to developing treatments for cancers affecting the peritoneum—the lining of the abdominal cavity.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> While sharing a surname with [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] (the thoracic surgeon who pioneered extrapleural pneumonectomy for pleural mesothelioma), the two physicians are not related and worked independently on different forms of the disease.

Dr. Paul H. Sugarbaker's focus on peritoneal surface malignancies led him to recognize that traditional systemic chemotherapy was largely ineffective for cancers confined to the abdominal cavity. The peritoneum's unique anatomy—a closed space where tumors spread along surfaces rather than through the bloodstream—required a completely different treatment approach.<ref>[https://www.cancer.gov/about-cancer/treatment/types/chemotherapy Chemotherapy to Treat Cancer], National Cancer Institute</ref>

{| style="width:95%; margin:1em auto; background:#f8f9fa; color:#333333; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Dr. Paul H. Sugarbaker's work gave peritoneal mesothelioma patients something that didn't exist before: a chance at long-term survival. Before HIPEC, this diagnosis was essentially a death sentence. Now we can tell patients about a treatment that has helped some people live seven years or more."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
|}

== What Is the Sugarbaker Procedure? ==

The Sugarbaker procedure combines two treatment modalities that work synergistically to treat peritoneal mesothelioma:<ref>[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref>

=== Cytoreductive Surgery (CRS) ===

The first component involves surgically removing all visible tumor from the abdominal cavity. This includes:

* Stripping affected peritoneal surfaces
* Removing involved organs or portions of organs when necessary
* Eliminating all macroscopic (visible) disease

The goal is complete cytoreduction—leaving no visible cancer behind. The completeness of cytoreduction is the single most important factor determining patient outcomes.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cytoreductive-surgery Cytoreductive Surgery Definition], NCI Dictionary</ref>

=== Hyperthermic Intraperitoneal Chemotherapy (HIPEC) ===

Immediately following cytoreductive surgery, while the patient is still in the operating room, heated chemotherapy solution is circulated throughout the abdominal cavity for 90 minutes.

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | HIPEC Parameter
! style="background:#1a5276; color:white; padding:10px;" | Specification
|-
| style="padding:10px;" | Temperature
| style="padding:10px;" | 42-43°C (107-109°F)
|-
| style="padding:10px;" | Duration
| style="padding:10px;" | 90 minutes
|-
| style="padding:10px;" | Delivery
| style="padding:10px;" | Circulated through open abdomen
|-
| style="padding:10px;" | Chemotherapy Agents
| style="padding:10px;" | Varies by protocol (commonly mitomycin C, cisplatin)
|}

{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✅ Why Heat Matters:''' The elevated temperature of HIPEC serves multiple purposes. Heat directly kills cancer cells, increases chemotherapy penetration into remaining microscopic disease, and enhances drug effectiveness. The regional delivery allows higher drug concentrations than would be tolerable with IV chemotherapy.
|}

== What Survival Outcomes Has the Sugarbaker Procedure Achieved? ==

Dr. Sugarbaker's research demonstrated that patients could achieve survival ranging from 2.5 years at the low end to more than 7 years at the high end—a dramatic improvement over the historical prognosis of less than one year for peritoneal mesothelioma.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI SEER</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Factor
! style="background:#1a5276; color:white; padding:10px;" | Impact on Survival
|-
| style="padding:10px;" | Completeness of Cytoreduction
| style="padding:10px;" | '''Most important factor''' - complete visible removal essential
|-
| style="padding:10px;" | Histologic Subtype
| style="padding:10px;" | Epithelioid tumors respond better than sarcomatoid
|-
| style="padding:10px;" | Tumor Volume
| style="padding:10px;" | Lower volume disease has better outcomes
|-
| style="padding:10px;" | Lymph Node Status
| style="padding:10px;" | Node-negative patients do better
|-
| style="padding:10px;" | Treatment Center Experience
| style="padding:10px;" | High-volume centers achieve better results
|}

{| style="width:100%; background:#cce5ff; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#004085;" | '''ℹ️ Why Peritoneal Has Better Prognosis:''' Peritoneal mesothelioma generally has better survival outcomes than pleural mesothelioma. The abdominal cavity's anatomy allows for more complete surgical removal, and the disease tends to remain localized longer before spreading to distant sites.
|}

== Where Can Patients Access HIPEC Treatment Today? ==

The Sugarbaker procedure is now offered at specialized cancer centers throughout the United States.<ref>[https://www.cancer.gov/research/nci-role/cancer-centers NCI-Designated Cancer Centers], National Cancer Institute</ref> Because of its complexity, HIPEC should only be performed at high-volume centers with experienced surgical teams.

'''Leading HIPEC Centers Include:'''

* University of Chicago Medicine
* Memorial Sloan Kettering Cancer Center
* MD Anderson Cancer Center
* Washington Cancer Institute
* Wake Forest Baptist Medical Center

{| style="width:100%; background:#fff3cd; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#856404;" | '''⚠️ Center Selection Matters:''' Outcomes for HIPEC are significantly better at experienced centers. Patients should seek evaluation at institutions that perform the procedure regularly and have published survival data for peritoneal mesothelioma patients.
|}

{| style="width:95%; margin:1em auto; background:#f8f9fa; color:#333333; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "When we help clients with peritoneal mesothelioma, one of our first discussions is about HIPEC and which centers have the most experience. Dr. Sugarbaker's procedure offers real hope, but getting the best outcomes means getting to the right treatment center. We help families navigate these critical decisions."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— David Foster,''' Client Advocate, Danziger & De Llano
|}

== What Is Dr. Paul H. Sugarbaker's Legacy? ==

Dr. Paul H. Sugarbaker's contributions fundamentally changed the prognosis for peritoneal mesothelioma patients:<ref>[https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/ VA Asbestos Exposure], U.S. Department of Veterans Affairs</ref>

'''Before the Sugarbaker Procedure:'''
* Peritoneal mesothelioma was uniformly fatal
* Median survival was less than one year
* No standard treatment existed
* Patients received only palliative care

'''After the Sugarbaker Procedure:'''
* Long-term survival became possible (5-7+ years)
* International treatment standards were established
* Specialized centers developed worldwide
* Patients have a fighting chance at extended life

His work demonstrates how a single researcher's dedication can transform outcomes for patients with rare diseases.<ref>[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration</ref>

== Get Help Today ==

If you or a loved one has been diagnosed with peritoneal mesothelioma, accessing specialized treatment—including the HIPEC procedure Dr. Sugarbaker developed—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your asbestos exposure.<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>

The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

📞 '''Call (866) 222-9990''' or [https://dandell.com/contact-us/ request a free case review online].

== See Also ==

* [[History_of_Mesothelioma_Research|History of Mesothelioma Research]]
* [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] (Pleural Mesothelioma Surgeon - Not Related)
* [[Peritoneal_Mesothelioma|Peritoneal Mesothelioma]]
* [[Treatment_Options|Treatment Options]]
* [[Mesothelioma_Treatment_Centers|Mesothelioma Treatment Centers]]

== References ==

<references />

[[Category:Mesothelioma Research]]
[[Category:Mesothelioma Researchers]]
[[Category:Mesothelioma]]
[[Category:Treatment History]]

← Older revision		Revision as of 14:28, 29 January 2026
Line 7:		Line 7:
	\|published_time=2026-01-28		\|published_time=2026-01-28
	}}		}}
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276~~; background:#ffffff; color:#333333~~; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Dr. Paul H. Sugarbaker, MD		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Dr. Paul H. Sugarbaker, MD
	\|-		\|-
	\| colspan="2" style="~~background:#e8f4f8; color:#333333;~~ padding:10px; text-align:center; font-style:italic;" \| Pioneer of Peritoneal Mesothelioma Treatment		\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| Pioneer of Peritoneal Mesothelioma Treatment
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Specialty		\| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" \| Specialty
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Surgical Oncology		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Surgical Oncology
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Key Innovation		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Key Innovation
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Cytoreductive Surgery + HIPEC		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Cytoreductive Surgery + HIPEC
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Procedure Named		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Procedure Named
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| The Sugarbaker Procedure		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| The Sugarbaker Procedure
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| HIPEC Temperature		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| HIPEC Temperature
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 42-43°C (107-109°F)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 42-43°C (107-109°F)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Survival Achieved		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Survival Achieved
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 2.5 to 7+ years		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 2.5 to 7+ years
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~;" \| Standard of Care		\| style="padding:10px; font-weight:bold; " \| Standard of Care
	\| style="padding:10px;" \| Endorsed by PSOGI		\| style="padding:10px;" \| Endorsed by PSOGI
	\|-		\|-
Line 48:		Line 48:
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Dr. Paul H. Sugarbaker's Contributions		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Dr. Paul H. Sugarbaker's Contributions
	\|-		\|-
	\| style="padding:15px~~; background:#f8f9fa; color:#333333~~;" \|		\| style="padding:15px; " \|
	* '''Key Innovation:''' Cytoreductive surgery combined with HIPEC for peritoneal mesothelioma		* '''Key Innovation:''' Cytoreductive surgery combined with HIPEC for peritoneal mesothelioma
	* '''Procedure Name:''' The Sugarbaker Procedure (named in his honor)		* '''Procedure Name:''' The Sugarbaker Procedure (named in his honor)
Line 67:		Line 67:
	Dr. Paul H. Sugarbaker's focus on peritoneal surface malignancies led him to recognize that traditional systemic chemotherapy was largely ineffective for cancers confined to the abdominal cavity. The peritoneum's unique anatomy—a closed space where tumors spread along surfaces rather than through the bloodstream—required a completely different treatment approach.<ref>[https://www.cancer.gov/about-cancer/treatment/types/chemotherapy Chemotherapy to Treat Cancer], National Cancer Institute</ref>		Dr. Paul H. Sugarbaker's focus on peritoneal surface malignancies led him to recognize that traditional systemic chemotherapy was largely ineffective for cancers confined to the abdominal cavity. The peritoneum's unique anatomy—a closed space where tumors spread along surfaces rather than through the bloodstream—required a completely different treatment approach.<ref>[https://www.cancer.gov/about-cancer/treatment/types/chemotherapy Chemotherapy to Treat Cancer], National Cancer Institute</ref>

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa; color:#333333~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Paul H. Sugarbaker's work gave peritoneal mesothelioma patients something that didn't exist before: a chance at long-term survival. Before HIPEC, this diagnosis was essentially a death sentence. Now we can tell patients about a treatment that has helped some people live seven years or more."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Paul H. Sugarbaker's work gave peritoneal mesothelioma patients something that didn't exist before: a chance at long-term survival. Before HIPEC, this diagnosis was essentially a death sentence. Now we can tell patients about a treatment that has helped some people live seven years or more."
Line 110:		Line 110:
	\|}		\|}

	{\| style="width:100%~~; background:#d4edda~~; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#155724~~;" \| '''✅ Why Heat Matters:''' The elevated temperature of HIPEC serves multiple purposes. Heat directly kills cancer cells, increases chemotherapy penetration into remaining microscopic disease, and enhances drug effectiveness. The regional delivery allows higher drug concentrations than would be tolerable with IV chemotherapy.		\| style="padding:15px; " \| '''✅ Why Heat Matters:''' The elevated temperature of HIPEC serves multiple purposes. Heat directly kills cancer cells, increases chemotherapy penetration into remaining microscopic disease, and enhances drug effectiveness. The regional delivery allows higher drug concentrations than would be tolerable with IV chemotherapy.
	\|}		\|}

Line 140:		Line 140:
	\|}		\|}

	{\| style="width:100%~~; background:#cce5ff~~; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#004085~~;" \| '''ℹ️ Why Peritoneal Has Better Prognosis:''' Peritoneal mesothelioma generally has better survival outcomes than pleural mesothelioma. The abdominal cavity's anatomy allows for more complete surgical removal, and the disease tends to remain localized longer before spreading to distant sites.		\| style="padding:15px; " \| '''ℹ️ Why Peritoneal Has Better Prognosis:''' Peritoneal mesothelioma generally has better survival outcomes than pleural mesothelioma. The abdominal cavity's anatomy allows for more complete surgical removal, and the disease tends to remain localized longer before spreading to distant sites.
	\|}		\|}

Line 157:		Line 157:
	* Wake Forest Baptist Medical Center		* Wake Forest Baptist Medical Center

	{\| style="width:100%~~; background:#fff3cd~~; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#856404~~;" \| '''⚠️ Center Selection Matters:''' Outcomes for HIPEC are significantly better at experienced centers. Patients should seek evaluation at institutions that perform the procedure regularly and have published survival data for peritoneal mesothelioma patients.		\| style="padding:15px; " \| '''⚠️ Center Selection Matters:''' Outcomes for HIPEC are significantly better at experienced centers. Patients should seek evaluation at institutions that perform the procedure regularly and have published survival data for peritoneal mesothelioma patients.
	\|}		\|}

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa; color:#333333~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "When we help clients with peritoneal mesothelioma, one of our first discussions is about HIPEC and which centers have the most experience. Dr. Sugarbaker's procedure offers real hope, but getting the best outcomes means getting to the right treatment center. We help families navigate these critical decisions."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "When we help clients with peritoneal mesothelioma, one of our first discussions is about HIPEC and which centers have the most experience. Dr. Sugarbaker's procedure offers real hope, but getting the best outcomes means getting to the right treatment center. We help families navigate these critical decisions."